Home › Follicular Lymphoma › Washington › Seattle
Follicular Lymphoma clinical trials in Seattle, WA
16 studies for Follicular Lymphoma are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- Swedish Cancer Institute (SCI), Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
- Swedish Medical Center-First Hill, Seattle
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Fred Hutch Cancer Center, Seattle
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
- Research Site, Seattle
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RecruitingPhase 2Healthy volunteers welcome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- Swedish Cancer Institute, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Recruiting
- University of Washington Medical Center, Seattle
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Houston, TX20 studies
- Milwaukee, WI19 studies
- Nashville, TN18 studies
- Baldwin Park, CA16 studies
- Boston, MA16 studies
- Durham, NC16 studies
- Salt Lake City, UT13 studies
- Columbus, OH13 studies
- Los Angeles, CA13 studies
- Chicago, IL12 studies
- San Antonio, TX12 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.